---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006907"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:22:49.589209+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaxart initiates Phase 1 trial for oral norovirus vaccine; topline data expected mid-2025

## Summary
- Phase 1 open-label dose-ranging trial evaluating second-generation oral norovirus pill vaccine vs first-generation constructs.
- Topline data expected as early as mid-2025.
- If successful, Phase 2 could start H2 2025, Phase 3 as early as 2026, subject to partnership or other funding.
- No vaccines currently approved for norovirus; Vaxart's oral pill is the only clinical-stage candidate.
- CEO Steven Lo cites urgent public health need as norovirus spreads globally.

## SEC filing metadata
- accession: 0001437749-25-006907
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925006907/0001437749-25-006907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925006907/vxrt20250310_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006907
- JSON: https://secwatch.observer/filing/0001437749-25-006907.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.